Science Current Events | Science News |

Rejected Alzheimer's drug shows new potential

July 31, 2012
Study suggests that latrepirdine, which previously failed in clinical trials, may be successful if tested on patients with earlier stages of the disease

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease. The findings, published July 31, 2012 in Molecular Psychiatry, demonstrate renewed potential for this compound and could lead to clinical trials in patients with early stages of the disease.

Latrepirdine, known commercially as Dimebon, was initially sold as an antihistamine in Russia, approved for use there in 1983. In the 1990s, researchers at the Institute of Physiologically Active Compounds in Moscow determined that the compound appeared effective in treating Alzheimer's disease in animals. They continued their research in humans and performed several studies, including Phase I and II trials, all of which showed significant and sustained improvement in cognitive behavior with minimal side effects. The Phase II trials, performed in Russia, were overseen by U.S. Alzheimer's researchers, including Mary Sano, PhD, Director of the Mount Sinai Alzheimer's Disease Research Center.

However, when research was continued in the United States in a Phase III trial, the drug did not demonstrate any improvement in people with the disease, causing the sponsors to halt further clinical study of the drug in Alzheimer's disease. Some researchers have speculated that the Russian patients might have had different disease stage or subtype of Alzheimer's, and therefore were more responsive to treatment than the patients in the Phase III trials in the United States.

Before the failed trials were announced, researchers at Mount Sinai School of Medicine, led by Sam Gandy, MD, PhD, Professor of Neurology, and Psychiatry, and Director of the Mount Sinai Center for Cognitive Health, began studying the mechanism of action behind latrepirdine in the current study, which is supported by the Cure Alzheimer's Fund.

Dr. Gandy's team randomly administered either latrepirdine or placebo to mice engineered to present the early stages of Alzheimer's disease and found that the drug halted both behavioral decline and progression of neuropathology. In evaluating how latrepirdine improved memory, John Steele, PhD, a neuroscience graduate student working with Dr. Gandy, and Lenard Lachenmayer, MD, a postdoctoral fellow working under the supervision of Zhenyu Yue, PhD, Associate Professor of Neurology at Mount Sinai, found that the drug enhanced autophagy, the so-called "self-eating" process of cells that protects the brain from neurodegeneration.

"When we learned that latrepirdine failed in patients in the United States in 2010, scientists around the world were disappointed and perplexed," Dr. Gandy said. "We wanted to find out why the drug did so well in Russia but then showed no effect in the global studies. The findings from our animal model studies indicated that this drug should not be discarded, and that, if its mechanism of action can be optimized, it still has potential."

Dr. Sano points out that not only did latrepirdene have significant and sustained effect in the Russian study but it also showed a mild effect in one study of patients with Huntington's disease.

"Since cognitive benefit is what really matters to patients and families, it is critical that we explore every mechanism by which it might occur," Dr. Sano said.

"While this is just the beginning, our research shows that this previously cast-off drug still has strong therapeutic promise," Dr. Gandy said. "Autophagy drugs are believed to hold great promise for a range of neurodegenerative diseases, and these data raise the question of whether further basic science work on latrepirdine might lead to optimization of the drug so that a more potent drug could be developed, and subsequently tested in human clinical trials.

"This is especially true since we know that latrepirdine is an extremely safe drug and in view of the recent failure of the first key trial of the drug bapineuzumab," Dr. Gandy added. "Also, as may be the case with all amyloid-lowering drugs, initiating latrepirdine trials before amyloid deposition begins may be the key. Now, with the new brain amyloid scans that began at Mount Sinai in June, we can easily establish who those patients are."

Looking ahead, Drs. Gandy, Yue, and their collaborators are planning to test latrepirdine in mouse models of other protein buildup diseases such as Parkinson's disease, Lewy body dementia, and chronic traumatic encephalopathy, the Alzheimer's-like condition athletes endure from boxing, football and hockey. Dr. Sano notes that so few agents show any improvement in cognition that it is critical that to exhaust every potential lead.

Mount Sinai has a long-standing legacy of critical breakthroughs in team research in Alzheimer's disease. Dr. Gandy is an internationally-renowned expert in understanding the amyloid plaques characteristic of Alzheimer's disease, and he led a team of researchers to the discovery of the first drugs that reduced amyloid buildup. Dr. Sano is a world leader in designing clinical trials to find treatments and preventions for cognitive loss and Alzheimer's disease. Together, their labs and the Mount Sinai Alzheimer's Disease Research Center and Center for Cognitive Health are focused on a strategic approach to translating clinical challenges into bench investigations and back.

The Mount Sinai Hospital / Mount Sinai School of Medicine

Related Alzheimer's Disease Current Events and Alzheimer's Disease News Articles

Immune gene prevents Parkinson's disease and dementia
An estimated seven to ten million people worldwide are living with Parkinson's disease (PD), which is an incurable and progressive disease of the nervous system affecting movement and cognitive function.

MS may start later for those who spend teenage summers in the sun
A study of people with multiple sclerosis (MS) found that those who spent time in the sun every day during the summer as teens developed the disease later than those reporting not spending time in the sun every day.

Medical diagnosis: Will brain palpation soon be possible?
If there is one technique used by the physician to explore the human body during every medical examination in order to make a diagnosis or prescribe further tests, it is palpation.

New study reveals limited public understanding of dementia globally
Believing that dementia is a normal part of aging is the most common misconception about dementia, according to a new study conducted by researchers at Trinity College Dublin and St James's Hospital's Dementia Services Centre in Ireland.

Horse sickness shares signs of human brain disorders, study finds
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer's, a study has found.

Benzodiazepines ineffective in treating anxiety disorders and may increase dementia risk
Patients taking benzodiazepines to treat psychiatric conditions should consider transitioning to other therapies because of heightened risks for dementia and death, according to clinicians from the American College of Osteopathic Neurologists and Psychiatrists.

Women with Alzheimer's-related gene lose weight more sharply after age 70
Researchers led by Deborah Gustafson, PhD, MS, professor of neurology at SUNY Downstate Medical Center, have shown that women with a gene variant (APOEe4 allele) associated with Alzheimer's disease experience a steeper decline in body mass index (BMI) after age 70 than those women without the version of the gene, whether they go on to develop dementia or not.

Drug used to treat cancer appears to sharpen memory
Can you imagine a drug that would make it easier to learn a language, sharpen your memory and help those with dementia and Alzheimer's disease by rewiring the brain and keeping neurons alive?

Face-to-face socializing more powerful than phone calls, emails in guarding against depression
In a slight knock on digital and telephone communications, a new study points to the unsurpassed mental health benefits of regular face-to-face social interactions among older adults.

Dormant viral genes may awaken to cause ALS
Scientists at the National Institutes of Health discovered that reactivation of ancient viral genes embedded in the human genome may cause the destruction of neurons in some forms of amyotrophic lateral sclerosis (ALS).
More Alzheimer's Disease Current Events and Alzheimer's Disease News Articles

Alzheimer 's Disease and Risks: Simplified

Alzheimer 's Disease and Risks: Simplified

This book is a comprehensive guide and review for anyone who wishes to learn about the Alzheimer’s disease. You may have someone in the family who suffers from it or you may just be curious to learn about it. Regardless, this book is sure to benefit you by providing you a complete interface of the disease. We will start from the very basics on what the disease actually is, how it starts and its scientific mechanism in comprehensive way.
In addition, the signs and symptoms will be talked about in detail in order to enable you to make an efficient diagnosis if you come across such an individual. We will also talk about who is more likely to be affected by it, how it can be treated, prevented and how to deal with it. This will be in terms of both the patient as well as the family....

The Alzheimer's Diet: A Step-by-Step Nutritional Approach for Memory Loss Prevention and Treatment (Volume 1)

The Alzheimer's Diet: A Step-by-Step Nutritional Approach for Memory Loss Prevention and Treatment (Volume 1)
by Richard S Isaacson MD (Author), Christopher N Ochner PhD (Author)

Harvard-trained Neurologist, Dr. Richard Isaacson and renowned nutrition expert, Dr. Christopher Ochner team up to create this ground-breaking nutritional guide for individuals concerned about memory loss. In recent years, there has been an explosion in research on nutritional interventions for Alzheimer’s prevention and treatment, which is considered to be the most severe public health crisis of our day. These specific dietary interventions present new hope for individuals concerned about memory loss, and also have rapidly expanding scientific-evidence to support their effectiveness. Based on empirical evidence, The Alzheimer’s Diet outlines what to eat, what not to eat, and highlights a step-by-step approach for improving memory and protecting the brain through diet. This...

Virgin Coconut Oil and Alzheimer's Disease: A Holistic Guide to Geriatric Care

Virgin Coconut Oil and Alzheimer's Disease: A Holistic Guide to Geriatric Care
by Sophia Media, LLC

Alzheimer's Disease is a modern plague on the seniors in our society. More evidence continues to be published that Alzheimer's is primarily a prescription drug induced disease. Today's average senior living in a healthcare facility is taking an average of over 30 different prescription drugs. Yet, their quality of life is not as good as previous generations according to researchers.

More than 5 million Americans are living with the Alzheimer’s Disease, and the official statement from the medical establishment is: “Currently, there is no cure for Alzheimer's.”

What they mean is, there is no drug that can cure Alzheimer's. However, thousands of people around the world are seeing great success with non-drug alternatives, and coconut oil tops the list.
The Longest Loss: Alzheimer's Disease and Dementia

The Longest Loss: Alzheimer's Disease and Dementia
by Hospice Foundation of America (Author), Kenneth J. Doka and Amy S. Tucci (Editor)

Grief and loss begins at the onset of Alzheimer's disease and dementia, following the individual, family members and caregivers down an uncertain path. This volume is a collection of chapters written by experts and real people who understand and validate that grief. Authors also offer advice regarding how to cope with specific challenges posed by Alzheimer's and dementia. Helpful to practicing clinicians and people who are living with or caring for individuals living with Alzheimer's or a related dementia.

Alzheimer's Disease: What If There Was a Cure?

Alzheimer's Disease: What If There Was a Cure?
by Mary T. Newport (Author), Cheryl Hirsch (Editor)

Though Dr. Mary T. Newport has provided professional care to newborns since 1983, she's led a double life since 2000 when she became a caregiver at home. That's when her beloved husband, Steve, first showed signs of Alzheimer's disease. After his deterioration accelerated in 2004, Dr. Newport began avidly researching ways to keep him functional for as long as possible. Since she understands medical terminology and scientific methods, she was thrilled to find new research showing that medium- chain fatty acids, which act like an alternative fuel in the insulin-deficient Alzheimer's brain, can sometimes reverse or at least stabilize the disease. When she gave Steve about 2 tablespoons of coconut oil (a source of these fats) at breakfast before a memory test that he had previously failed,...

Alzheimer's Disease: What If There Was a Cure?

Alzheimer's Disease: What If There Was a Cure?
by Mary T. Newport (Author)

The first edition of Alzheimer's Disease: What if There Was a Cure?, which details Dr. Newport's discovery and use of medium-chain fatty acids (which act like alternative fuel in the Alzheimer's brain), had such a strong reception in 2011 that a second edition is now in demand. In this updated and expanded version, Dr. Newport, a neonatal practitioner, continues the story of her husband Steve's progress and provides the most recent research on the possible connection between Alzheimer's disease and the herpes simplex virus and nitrosamine substances, as well as how infection, inflammation, and genetic makeup may affect an individual's response to fatty acid therapy. Among many other updates, Dr. Newport details the latest clinicaltrials aimed at removing beta-amyloid, which accumulates in...

Alzheimer's Treatment Alzheimer's Prevention: A Patient and Family Guide, 2012 Edition

Alzheimer's Treatment Alzheimer's Prevention: A Patient and Family Guide, 2012 Edition
by Dr. Richard S Isaacson MD (Author)

Harvard-trained Neurologist Dr. Richard Isaacson answers the most common patient and caregiver questions on the treatment and prevention of Alzheimer's disease (AD). He shares his cutting edge, comprehensive approach in the fight against AD, the greatest public health crisis today. This groundbreaking book has been written especially for patients, caregivers, family members, and allied healthcare professionals. Dr. Isaacson writes in easy to understand terms and easy to read (larger-type) print to help educate and inform those confronting AD. He outlines his comprehensive and scientifically-based approach that includes a comprehenisve 9-week diet and nutrition plan, with examples of what to eat, what not to eat, and a food terminology guide to help read and understand nutrition labels. ...

Outsmarting Alzheimer's: What You Can Do To Reduce Your Risk

Outsmarting Alzheimer's: What You Can Do To Reduce Your Risk
by M.D. Kenneth S. Kosik (Author)

An easy-to-follow, research-based guide to the simple, low-cost choices that give the reader the power to reduce the risk of developing Alzheimer's disease and dementia; slow the progression of the disease; and mitigate symptoms and improve well-being.

Did you know that getting on the treadmill can help keep your brain sharp? Or that repeatedly staying up to catch the late show could increase the likelihood of being struck down by dementia? The dozens of choices you make over the course of any average day—ordering the curry versus the burger with fries, taking the stairs versus the elevator—all add up. Together with your family history, they establish your chances of getting Alzheimer’s years from now. No drugs or procedures can cure or even effectively treat Alzheimer’s...

Living With Alzheimer?s Disease: A Complete Guide to Caring for Someone with Alzheimer's

Living With Alzheimer?s Disease: A Complete Guide to Caring for Someone with Alzheimer's
by Linda H. Harris (Author)

Alzheimer's Disease is a progressive form of dementia that kills brain cells, leading to continual loss of memory, intellectual capacity, and eventual death. Sadly, no treatment has been found to stop its progression. "Living with Alzheimer's Disease: A Complete Guide to Caring for Someone with Alzheimer's" provides a valuable resource for individuals struggling with the effects of Alzheimer's, and those who care for them. This book is filled with current information to help sufferers and their caretakers understand the many facets and stages of the disease. It explains initial signs that there may be a problem, diagnosis, the different stages, symptoms and suggestions for coping with them, and varied treatment plans, including helpful diet modifications. It compassionately provides...

Second Forgetting: Remembering the Power of the Gospel during Alzheimer's Disease

Second Forgetting: Remembering the Power of the Gospel during Alzheimer's Disease
by Dr. Benjamin T. Mast (Author), Scotty Smith (Foreword)

Charles is 78 years old and there is much he cannot remember. He cannot remember the names of his children, why he lives in a nursing home, or even whether he ate breakfast today. His forgetting causes confusion, and in his fear and uncertainty he sometimes lashes out at those who try to care for him. But when someone reads a favorite Psalm he quickly joins in, reciting each cherished word. When he hears an old hymn of faith, his hand slowly raises and he breathes out each word quietly, his face reflecting a peace that passes all understanding. Alzheimer’s disease has been described as the “defining disease” of the baby boomer generation. Millions of Americans will spend much of their retirement years either caring for a loved one with Alzheimer’s disease or experiencing its...

© 2015